Abstract: Provided herein are coacervate compositions including cytokines, and methods of making and using the same. The coacervate can be formed by the mixing of an active agent, such as a drug or protein with the polyanion, such as heparin or heparan sulfate, and a custom-made polycation (e.g., PEAD or PELD). The coacervates can be used in the treatment of diseases and disorders where targeted treatment is desired, for example in treatment of cancers.
Type:
Grant
Filed:
June 4, 2021
Date of Patent:
October 10, 2023
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Abstract: An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.
Type:
Grant
Filed:
April 6, 2020
Date of Patent:
September 12, 2023
Assignee:
UNIVERSITY OF UTAH RESEARCH FOUNDATION
Inventors:
Christian Con Yost, Guy A. Zimmerman, Andrew S. Weyrich
Abstract: Provided are methods for quantitating an amount of a polypeptide that comprises a portion of an antibody present in a sample (e.g., a plasma or serum sample) wherein the antibody comprises a constant region (e.g., a heavy chain or light chain constant region) that comprises an engineered mutation.
Abstract: Disclosed are compositions and methods involving the use of PRG4 protein, also known as lubricin, to mechanically inhibit biological processes involving cell motility and adhesion. The methods and compositions may be used to develop a variety of specific therapies and compositions, often exploited through surgical procedures, where development of the pathology involves one or more of the following modes of action: 1) the passage of cells from one body compartment to another, 2) adherence of macrophages to substrates such as fibrin or exposed extra cellular matrix, 3) binding of platelets to fibrin, or 4) failure of function of the glycocalyx on exposed epithelial cell surfaces, e.g., within the vasculature.
Type:
Grant
Filed:
March 9, 2021
Date of Patent:
September 12, 2023
Assignee:
Lubris LLC
Inventors:
Gregory D. Jay, Tannin A. Schmidt, Benjamin D. Sullivan
Abstract: Method of increasing platelet counts in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound that inhibits Biliverdin reductase B (BLVRB) activity by blocking a binding site of BLVRB or a pharmaceutically acceptable salt thereof, wherein the compound does not contain xanthene or acridine moiety is provided.
Type:
Grant
Filed:
April 7, 2021
Date of Patent:
September 5, 2023
Assignees:
KOREA BASIC SCIENCE INSTITUTE, University of Louisville Research Foundation, Inc., Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
Inventors:
Kyoung-Seok Ryu, Myeongkyu Kim, Christian Griesinger, Donghan Lee
Abstract: The present invention relates to polypeptides and analogues thereof for use in the treatment of diabetes and bone disorders. Also disclosed are pharmaceutical compositions comprising the polypeptides and analogues thereof, and methods for the treatment of diabetes and bone disorders.
Abstract: The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.
Type:
Grant
Filed:
May 21, 2021
Date of Patent:
August 29, 2023
Assignee:
OCTAPHARMA AG
Inventors:
Christoph Kannicht, Stefan Winge, Guido Kohla, Barbara Solecka-Witulska
Abstract: Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.
Type:
Grant
Filed:
May 3, 2021
Date of Patent:
August 29, 2023
Assignee:
Eiger Biopharmaceuticals, Inc.
Inventors:
Xiaofeng Xiong, Debra Odink, Colleen M. Craig, Christine M. N. Smith, Tracey L. McLaughlin
Abstract: Provided herein are water soluble salts of Formula I, wherein R1, A, and M are defined herein. Also provided herein are methods of preparing the salts of Formula I and methods of using the same.
Abstract: The present application provides stable peptide-based Botulinum neurotoxin (BoNT) serotype A capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing BoNT serotype A capture agents using iterative on-bead in situ click chemistry.
Type:
Grant
Filed:
May 17, 2021
Date of Patent:
August 15, 2023
Assignees:
INDI MOLECULAR, INC., CALIFORNIA INSTITUTE OF TECHNOLOGY
Inventors:
Blake Farrow, James R. Heath, Heather Dawn Agnew
Abstract: A method of treating systemic lupus erythematosus in a subject is provided in which a therapeutically effective amount of PIC1 is administered to the subject. A method of treating transfusion-related acute lung injury is also provided where a therapeutically effective amount of PIC1 is administered to the subject. PIC1 can modulate immune complex activation of the complement system and NET formation in the subject. PIC1 can also inhibit myeloperoxidase (MPO) activity in the subject.
Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.
Type:
Grant
Filed:
January 7, 2021
Date of Patent:
July 25, 2023
Assignee:
Ra Pharmaceuticals, Inc.
Inventors:
Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter
Abstract: Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).
Type:
Grant
Filed:
February 27, 2020
Date of Patent:
July 18, 2023
Assignee:
SYNTHORX, INC.
Inventors:
Jerod Ptacin, Carolina E. Caffaro, Marcos Milla
Abstract: A portable and mobile bioprocessing system and method for protein manufacturing that is compact, integrated and suited for on-demand production of any type of proteins and for delivery of the produced proteins to patients or for assay purposes. The portable system and method can also be used for efficient on-demand production of any type of protein with point-of-care delivery.
Type:
Grant
Filed:
July 15, 2021
Date of Patent:
July 18, 2023
Assignee:
University of Maryland, Baltimore County
Abstract: A preparation method of a novel natural bioactive peptide Tubulysin U includes: dissolving a compound 2 in trifluoroacetic acid, heating under reflux to prepare an intermediate, reacting with a compound 3 and N,N-diisopropylethylamine to obtain a product, reacting the product with 2, 6-dimethylpyridine and tert-butyldimethylsilyl trifluoromethanesulfonate, adding sodium hydroxide after the reaction to prepare an intermediate acid, reacting the intermediate acid with a compound 6, HATU and N,N-diisopropylethylamine to obtain a product, adding triphenylphosphine to prepare an intermediate amine, adding a compound 8 and HATU to react, adding ammonium fluoride to prepare a first intermediate, adding sodium hydroxide to the first intermediate to prepare a second intermediate, adding acetic anhydride to the second intermediate to prepare a third intermediate, adding trifluoroacetic acid to the third intermediate to prepare a fourth intermediate, and adding formaldehyde and sodium cyanoborohydride to the fourth inte
Abstract: A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to ?-melanocortin stimulating hormone (?-MSH).
Type:
Grant
Filed:
November 13, 2020
Date of Patent:
July 18, 2023
Assignee:
RHYTHM PHARMACEUTICALS, INC.
Inventors:
Louis Anthony Tartaglia, Bart Henderson, Leonardus H. T. Van Der Ploeg
Abstract: The present invention provides nucleic acid templates (e.g., including orthogonal codon sets (e.g., codons from orthogonal codon sets depicted in Tables 5 or 7)) for DNA-templated methods of synthesizing, selecting, and amplifying compounds (e.g., polymers and/or small molecules) described herein. Also provided are novel macrocyclic compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, libraries, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing a disease (e.g., a disease associated with aberrant enzyme activity (e.g., aberrant protease and/or kinase activity (e.g., aberrant IDE activity)), impaired insulin signaling, or insulin resistance in a subject (e.g., a subject having diabetes).
Type:
Grant
Filed:
February 8, 2019
Date of Patent:
June 13, 2023
Assignee:
President and Fellows of Harvard College
Inventors:
David R. Liu, Dmitry L. Usanov, Juan Pablo Maianti, Alix I. Chan
Abstract: The invention provides a BASEHIT screening method for identifying proteins that are involved in host-microbe interactions which may function as therapeutic targets.